Key facts
- This page summarizes Ugur Sahin's Form 3 filing for BioNTech SE (BNTX).
- 0 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 25 Mar 2026, 18:00.
Ugur Sahin - 18 Mar 2026 Form 3 Insider Report for BioNTech SE (BNTX)
- Reporting relationship
- Chief Executive Officer, 10%+ Owner
- Issuer ticker
- BNTX
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Humza Bokhari, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Ugur Sahin filed Form 3 for BioNTech SE (BNTX) on 25 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002123975
Primary reporting owner
Sahin Ugur
- Relationship
- Chief Executive Officer, 10%+ Owner
- Address
- C/O BIONTECH SE, AN DER GOLDGRUBE 12, MAINZ, GERMANY
- Signature
- /s/ Humza Bokhari, Attorney-in-Fact
- Signature date
- 25 Mar 2026
This filing has been restated.
Open the amended filing.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BNTX
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 40,132,788
- Date
- 18 Mar 2026
- Ownership
- See Footnote
- Footnotes
- F1
BNTX
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 858,209
- Date
- 18 Mar 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BNTX
holding
Derivative
Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 38,506
- Exercise price
- $113.94
- Footnotes
- F2, F3, F4
BNTX
holding
Derivative
Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 53,233
- Exercise price
- Footnotes
- F2, F3, F4, F5
BNTX
holding
Derivative
Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 18,747
- Exercise price
- Footnotes
- F2, F3, F4, F6
BNTX
holding
Derivative
Phantom Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 17,780
- Exercise price
- $185.23
- Footnotes
- F2, F4, F7
BNTX
holding
Derivative
Phantom Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 19,997
- Exercise price
- $152.10
- Footnotes
- F2, F4, F7
BNTX
holding
Derivative
Performance Share Unit
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 23,434
- Exercise price
- $0.000000
- Footnotes
- F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
The ordinary shares are held by Medine GmbH. The Reporting Person is the sole shareholder of Medine GmbH. 1,021,398 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The Reporting Person may be deemed to beneficially own the ordinary shares held by Medine GmbH.
Footnote F2
The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.
Footnote F3
The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board.
Footnote F4
Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price.
Footnote F5
The exercise price of this option is EUR 75.91.
Footnote F6
The exercise price of this option is EUR 93.35.
Footnote F7
Each phantom option represents the right to receive a cash payment equal to the difference between an exercise closing price (average closing price of an ADS over the last ten trading days preceding the exercise date) and the exercise price.
Footnote F8
Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.
SEC remarks
Exhibit List - Exhibit 24 - Power of Attorney